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Abstract
Major depressive disorder and the anxiety disorders are highly prevalent, disabling and moderately heritable. Depression
and anxiety are also highly comorbid and have a strong genetic correlation (rg ≈ 1). Cognitive behavioural therapy is a
leading evidence-based treatment but has variable outcomes. Currently, there are no strong predictors of outcome.
Therapygenetics research aims to identify genetic predictors of prognosis following therapy. We performed genome-wide
association meta-analyses of symptoms following cognitive behavioural therapy in adults with anxiety disorders (n= 972),
adults with major depressive disorder (n= 832) and children with anxiety disorders (n= 920; meta-analysis n= 2724). We
estimated the variance in therapy outcomes that could be explained by common genetic variants (h2SNP) and polygenic
scoring was used to examine genetic associations between therapy outcomes and psychopathology, personality and
learning. No single nucleotide polymorphisms were strongly associated with treatment outcomes. No signiﬁcant estimate
of h2SNP could be obtained, suggesting the heritability of therapy outcome is smaller than our analysis was powered to
detect. Polygenic scoring failed to detect genetic overlap between therapy outcome and psychopathology, personality or
learning. This study is the largest therapygenetics study to date. Results are consistent with previous, similarly powered
genome-wide association studies of complex traits.
Introduction
Major depressive disorder (MDD) and the anxiety dis-
orders are the most prevalent psychiatric disorders (life-
time prevalence: 17% and ~30%, respectively1,2). These
common mental disorders account for more than 100
million disability-adjusted life years globally, and cost the
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UK National Health Service ~£30 billion per year3,4. MDD
and the anxiety disorders share several features. They are
more common in females, have an early age of onset in
adolescence or early adulthood, and can persist
throughout life, predicting further emotional difﬁculties
and considerable impairment1,5,6. For example, at 10 years
of follow up, only ~10% of adolescents diagnosed with an
anxiety disorder were disorder free, ~40% still suffered
with the same disorder and more than 60% reported a
second diagnosis, most commonly MDD7,8. MDD and the
anxiety disorders are heritable. Twin heritability ranges
from 30 to 60%9,10, and SNP heritability (h2SNP) ranges
from 15 to 30%11–13. The comorbidity between MDD and
the anxiety disorders is primarily explained by shared
genetic vulnerability. Twin and molecular genetic studies
consistently show that MDD and the anxiety disorders
have a genetic correlation (rg) that is not signiﬁcantly
different from one11,14–16.
Cognitive behavioural therapy (CBT) is an evidence-
based psychological therapy used to treat anxiety and
depressive disorders. It is a structured, goal-oriented,
skills-based treatment that has moderate-large effect sizes
(hedges g= 0.6–0.8)17, and is generally successful (i.e.,
leads to remission) in ~50% of patients with anxiety or
depression18,19. The treatment components of CBT vary
and are tailored to reﬂect disorder-speciﬁc symptoms or
problems. They typically involve psychoeducation, cog-
nitive restructuring, behavioural modiﬁcation (including
exposure to feared stimuli) and relaxation and/or coping
strategies. These processes aim to teach the individual to
challenge maladaptive responses by modifying negative
and anxiety-driven thoughts and behaviours20. Studies
examining outcomes following different CBT modalities
report comparable effect sizes17,18,21–27. Nonetheless,
substantial heterogeneity in outcomes indicates that the
efﬁcacy of psychological therapy can vary considerably for
different people.
Several patient characteristics are known to inﬂuence
therapy outcomes. Greater baseline severity, comorbidity
with other mental disorders, poor adherence with treat-
ment, unemployment, lower educational attainment and
cognitive ability, and interpersonal difﬁculties are asso-
ciated with poorer therapy outcome in adults28–32. Simi-
larly, greater baseline severity, comorbid psychopathology,
and poor perseverance with treatment are associated with
poorer therapeutic outcomes in clinically anxious chil-
dren33–36.
Therapygenetics is a relatively new ﬁeld, which inves-
tigates the relationship between genetic variation and
outcomes following psychological therapy37,38. We expect
that change in symptoms after therapy, like many changes
in response to the environment, has a genetic component.
Therapy outcomes are inﬂuenced by psychiatric, beha-
vioural and cognitive traits, all of which we know are
inﬂuenced by genetics9,14. The earliest evidence for a
contribution of genetics to outcomes following therapy
comes from candidate gene studies37. However, many
candidate gene associations have failed to replicate39. As
with most other complex traits, the genetic effects that
inﬂuence therapy outcomes are likely to be individually
small and dispersed across the genome. This means that
analyses should focus on genome-wide variation. The ﬁrst
genome-wide association study (GWAS) of outcomes
following psychological therapy was in children with
anxiety disorders (n= 939 at post-treatment)40. No sig-
niﬁcant genetic associations with therapy outcome were
observed, although three independent loci were of sug-
gestive signiﬁcance (P < 5 × 10−6). A second therapy out-
come GWAS, which was part of a broader gene
expression analysis (n= 182) also detected several loci
that were also of suggestive signiﬁcance (P < 5 × 10−6)41.
Such analyses require large samples to detect small
genetic effects at genome-wide signiﬁcance.
As seen in early GWAS of psychiatric disorders and
pharmacogenomics, available samples were often small
and underpowered to detect genetic associations42. While
progress has been slow to begin with, collaborative efforts
have led to larger samples, numerous genomic discoveries
and remarkable success for psychiatric genomics43. Stu-
dies examining genetic effects on outcomes following
antidepressant medication are beginning to catch up. A
meta-analysis of 2897 individuals was sufﬁcient to detect a
signiﬁcant heritability estimate for remission following
antidepressants (h2SNP= 0.42, SE= 0.18) and this was the
ﬁrst evidence of a genetic component for treatments
outcome of any kind44. A more recent study utilised
family data and clinical records (n= 4213) to examine
treatment resistant depression (or poor outcomes fol-
lowing antidepressant medication)45. They estimated a
pedigree-based heritability for treatment resistant
depression to be 0.6 (SE= 0.19) and subsequently detec-
ted signiﬁcant genetic correlations with neuroticism (rg=
0.66, SE= 0.26), mood disorder traits (rg= 0.86, SE=
0.36) and general psychopathology (rg= 0.96, SE= 0.26).
This suggests that lighter phenotyping in population-
based observational studies can be a valuable approach for
increasing sample size and holds promise for genomic
studies of treatment outcomes. It is important to build a
cohort sufﬁciently sized to obtain an estimate for the
genome-wide common variant heritability of therapeutic
outcome (i.e., how much variance in therapy outcome can
be explained by common genetic variation). This also
provides more robust evidence that a genetic component
exists and that genome-wide approaches hold potential as
prognostic predictors of symptoms following therapy.
Polygenic score analysis is one approach to improve
statistical power in small samples with genetic data. No
signiﬁcant polygenic score associations were detected
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with treatment outcome in the original child study.
However, a second study in the same sample found that
higher polygenic predisposition for environmental sensi-
tivity predicted better outcomes from high-intensity
therapies (R2 = 1.62%, P= 0.009), but poorer outcomes
from low-intensity therapies (R2= 4.80%, P < 7×10−5)46.
Recently, a polygenic score study of internet-delivered
CBT (iCBT) outcomes in adults with major depression (n
= 894) detected an interaction effect of a polygenic score
for autism spectrum disorder on symptomatic change
over time (β= 0.09, P < 0.001)47. This work suggests that
greater genetic predisposition for autistic traits may be
associated with poorer prognosis following treatment.
Here, we build on previous work, ﬁrst combining sev-
eral samples of individuals who have undergone a course
of CBT for an anxiety disorder (n= 972). We then meta-
analysed the results from the adult anxiety-CBT sample
with a sample of adults who completed a course of iCBT
for major depression (n= 832)47, and also with the child
anxiety-CBT sample (n= 920)40. This was done in order
to maximise our sample size (n= 2724) and power to
detect genetic effects.
There is evidence to suggest that outcomes following
psychological therapy are associated with three main groups
of variables. First is the general level of psychopathology, for
example, greater baseline severity and higher comorbidity
are both associated with poorer treatment outcomes28–30.
Second are personality characteristics, for example well-
being and belief in and/or adherence to treatment are
associated with outcome48–51. Finally, learning capacity is
likely to be relevant in that higher intelligence has been
associated with more favourable therapeutic outcomes30,
which makes sense given that learning is a core element of
CBT52. As such, we hypothesised that the genetic effects
that inﬂuence psychological therapy outcomes are likely to
be shared with psychopathology, personality and learning.
Polygenic score analyses were thus performed to test for
genetic associations between therapy outcomes and psy-
chopathology (ADHD53, anxiety disorders11, autism spec-
trum disorder54, major depressive disorder55,
schizophrenia56), personality (neuroticism57, subjective
well-being58, treatment-seeking behaviour59) and learning
(educational attainment60 and intelligence61).
Subjects and methods
Cohort descriptions
Adult anxiety sample
Participants (n= 972; 66.3% female; aged: 18–72, mean
= 36.3, SD= 11.3) were drawn from one of three broad
studies of CBT. Diagnoses were made according to DSM-
IV62 criteria using the the Mini-International Neu-
ropsychiatric Interview (MINI 5.0 or 6.0)63, the Diag-
nostisches Interview bei Psychischen Störungen (DIPS or
MINI-DIPS)64,65 or the Composite International
Diagnostic Interview (CIDI)66. The three predominant
disorders were panic disorder (PD= 37%), panic disorder
with agoraphobia (PD/AG= 42%), and speciﬁc phobia
(SP= 19%). These disorders share the common compo-
nents of excessive fear, anxiety, and avoidance behaviours.
All participants received CBT for an anxiety disorder. The
mode of treatment and the level of cognitive to beha-
vioural focus varied between clinics and treatment types.
All treatment programmes achieved comparable effect
sizes25,26,67,68. All participants were of White Western
European ancestry. Participants were not excluded for
taking psychotropic medications, but this was controlled
for in the subsequent analyses. The three primary
recruitment sites are each brieﬂy described below (see
Table 1 for an overview of the combined sample; see
Supplementary Material, S.Table 1 and the original papers
for further details25,26,67,68).
Cohort 1. Bochum and Braunschweig: Participants
completed one of four exposure-based CBT (eCBT)
treatment programmes at the Mental Health Research
and Treatment Centre, Ruhr-Universität Bochum, the
Dental Clinic Bochum or at the Technische Universität
Braunschweig, Germany (n= 283; 68% female;
aged:19–68, mean= 38.4, SD= 11.6). Treatment details
for each group are reported elsewhere41,68. In short, Ruhr-
University and Braunschweig patients received eCBT for
speciﬁc phobia, agoraphobia or panic disorder. Dental
Clinic patients received a shorter, dental-phobia speciﬁc
exposure treatment programme. The primary outcome
measure used to assess symptom severity was the
clinician-rated severity scale, Clinical Global Impression-
Severity (CGI-S). The CGI-S is an overall rating of anxiety
symptom severity and ranges from 1 to 7, whereby a score
of 1 indicates that the patient is healthy and a score of 7 is
indicative of severe illness69. The CGI-S was chosen due
to the range of anxiety disorders included, as it reﬂects
symptom severity in a disorder-independent fashion.
Cohort 2. Karolinska Institutet Panic Disorder iCBT:
Participants with panic disorder, were collected from the
university hospital psychiatric clinic in Stockholm, Swe-
den (n= 346; 59.6% female; aged:18–72, mean= 34.9, SD
= 10.6)26. A subset included participants from a rando-
mised controlled trial of internet delivered CBT (iCBT; n
= 60)25. The majority of the participants (n= 286) were
drawn from routine clinical care and had received iCBT.
The treatment content was identical in these groups. The
self-rated version of the Panic Disorder Severity Scale
(PDSS-SR)70 was used as the primary outcome measure.
The PDSS-SR has seven items, each with a 5-point scale,
ranging from 0–4, giving a total score range of 0–28. Cut-
off scores ≥9 suggest clinical levels of panic disorder71.
The scale assesses frequency and severity of panic attacks,
anticipatory anxiety, phobic avoidance and occupational
and social impairment.
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Cohort 3. Panic-Net Consortium: Participants with panic
disorder and agoraphobia were enrolled from two sub-
sequent multicentre, randomised controlled trials of
eCBT (n= 343; 72% female; aged:18–63, mean= 35.4, SD
= 10.8)67,72.The self-rated Panic Agoraphobia Scale (PAS,
one of the four primary outcome measures in this cohort)
was used in the present analysis73. The scale includes 14
items, the ﬁrst of which is a screening item, 13 of which
are used to determine symptom severity. Each item has a
scale of 0–4, with a maximum total score of 52. The scale
measures frequency, severity and duration of panic
attacks, agoraphobic avoidance, anticipatory anxiety,
impairment and worries about health.
Adult depression sample
Adults with MDD (n= 832; 65.5% female; aged:18–75,
mean= 37.9, SD= 11.8) were drawn from routine clinical
care, or from an online self-referral system and received
psychologist guided iCBT at the Internet Psychiatry Clinic
in Stockholm (see Table 1 for an overview; see original
papers for further details:26,47). Diagnoses were made
according to DSM-IV criteria62 using the Mini-
International Neuropsychiatric Interview63. The primary
outcome measure assessed was the Montgomery Åsberg
Depression Rating Scale-Self report (MADRS-S)74. The
MADRS-S total score, which ranges from 0 to 54, mea-
sures nine clinical characteristics of depression.
Child anxiety sample
Children (n= 920 at post-treatment; 55% female;
aged:5–17, mean= 9.8, SD= 2.2) with DSM-IV criteria
anxiety disorder diagnoses, received individual CBT (n=
251), group CBT (n= 484) or guided self-help/parent led
CBT (n= 204) at one of eleven sites36. Primary diagnoses
included generalised anxiety disorder (n= 339; 36.1%),
separation anxiety disorder (n= 220, 23.4%), social phobia
(n= 195, 20.8%), speciﬁc phobia (n= 105, 11.2%) or other
anxiety disorders (n= 80, 8.5%). Output from the Anxiety
Disorders Interview Schedule (ADIS) was converted into
Clinical Severity Ratings (CSR) on a scale of 0–8 (absent
to very severe; see Table 1 for an overview; see original
papers for further details36,40).
DNA extraction, genotyping
DNA extraction and genotyping processes are described
elsewhere40,41,47,75,76. In brief, of the adult anxiety sample,
DNA from 966 participants was extracted from blood by
routine desalting methods. For 6 Bochum participants and
28 Braunschweig participants (3.5% of total sample), DNA
was obtained from saliva samples. Genotyping of the
Bochum participants was performed using the Illumina
PsychChip microarray (Illumina, USA) at the Institute of
Psychiatry, Psychology and Neuroscience, King’s College
London41. Karolinska PD-iCBT samples were genotyped
on Illumina HumanOmniExpress BeadChips (Illumina,
USA) at the Department of Genomics, Life and Brain
Centre, University of Bonn, Germany. The Panic-Net
samples were genotyped using Illumina Human660W-
Quad BeadChips (Illumina, USA) and Sentrix BeadChip
Array HumanHap300 Genotyping BeadChips (Illumina,
USA) at the Department of Genomics, Life & Brain
Centre, University of Bonn, Germany76.
For the adult depression samples (n= 832), DNA was
extracted from blood. Genotyping was performed at LIFE
and BRAIN GmbH (Bonn, Germany) using the Inﬁnium
Global Screening Array 1.0 BeadArray (Illumina, Inc., San
Diego, CA, USA)47. For the child anxiety study (n= 920)
DNA was extracted from buccal swabs and saliva kits
(OG-500/PrepitL2P, DNAgenotek, Kanata, Canada).
Genotyping was performed on Illumina
HumanCoreExome-12v1.0 microarrays (Illumina, San
Diego, California, USA)(described in full40).
Genotype quality control and imputation
Quality control, implemented in PLINK 1.977,78 was
performed for each adult anxiety cohort (Bochum &
Braunschweig, Karolinska, Panicnet), the adult depression
sample, and child anxiety sample following a previously
published protocol79. Variants were excluded if they were
rare (minor allele frequency; MAF <0.05), deviated sub-
stantially from Hardy–Weinberg equilibrium (P < 10−5)
or were missing in >99% of participants. Participants were
removed if they had genotype calls for < 99% of variants,
were phenotype-genotype sex discordant (X chromosome
heterozygosity F statistic: males <0.8 and females >0.2
excluded), showed signs of cryptic relatedness or dupli-
cation (identity by descent: IBD >0.1875; IBD >3 SD from
the mean; genome-wide heterozygosity F statistic >3 SD
from the mean). The ancestry of participants was esti-
mated from their genotypes using principal component
analysis performed in EIGENSOFT80. Outliers were
removed if they were >6 SD from the mean on the ﬁrst
three principal components. Quality controlled data were
phased using SHAPEIT81 and imputed to the Haplotype
Reference Consortium reference panel82 using EAGLE
283, implemented on the Sanger Imputation server.
Genetic variants imputed with an info metric of <0.75, a
MAF of <0.05 or which were not present in >98% of the
sample were removed. Genotype data for the adult anxiety
sites was then merged using PLINK 1.977,78 and genetic
variants with MAF <0.05 or not present in >98% of the
sample were removed.
Ethics
All participants provided informed consent. This study
was conducted in accordance with the principles outlined
in the Declaration of Helsinki. All trials and collection of
samples were approved by site-speciﬁc human ethics and
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biosafety committees. Ethics approval for the Bochum and
Braunschweig studies was received from King’s College
London Psychiatry, Nursing and Midwifery Research
Ethics Sub-Committee and the Ethics Committee at the
Faculty of Psychology, Ruhr-Universität Bochum. The
BMBF “PanicNet” RCT project was approved by the
Ethics Committees of the Medical Faculty of the Tech-
nische Universität Dresden (EK 164082006) and the
German Psychological Society (AH11.2009) for wave I
and II, respectively. The Karolinska studies were approved
by the Regional Ethics Board in Stockholm, Sweden
(REPN 2009/1089–31/2, 2015/2091). The storage and
analysis of DNA was approved by the King’s College
London Psychiatry, Nursing and Midwifery Research
Ethics Sub-Committee.
Statistical analysis
Therapy outcome phenotypes
Outcome analyses examined change in symptom
severity from start-of-treatment (baseline) to end-of-
treatment (post-treatment). As continuous outcome
measures differed between cohorts, they were standar-
dised. Raw scores at baseline and at post-treatment were
divided by the cohort speciﬁc standard deviations of
baseline scores. Where there were no data at post-treat-
ment, data were imputed using the last observation
recorded. Dichotomised treatment outcomes and percent
change from baseline are often used in clinical decision
making in studies of treatment outcomes. However, both
of these approaches have been shown to attenuate sta-
tistical power84,85.
Clinical predictors of therapy outcome
The effects of clinical covariates on symptom severity at
baseline and post-treatment, and therapy outcomes were
assessed. Linear mixed models were used to control for
the random effects of cohort and site to account for
between-cohort and between-trial differences in out-
comes. All of the covariates, including age, sex, number of
comorbidities, number of therapy sessions, psychotropic
medication status, primary diagnosis and baseline sever-
ity, were entered concurrently. Thus any signiﬁcant
associations are controlled for all other covariates in the
model. These analyses were performed using the lme4
package in R.3.4.386,87.
Association with therapy outcome
All subsequent genomic analyses were performed on
the imputed, quality controlled genotype data in each
sample separately (adult anxiety sample, the adult
depression sample and the child anxiety sample), prior to
meta-analyses. Therapy outcome phenotypes for each
sample were derived from the residuals of linear regres-
sions of the standardised post-treatment scores on the
independent covariates (standardised baseline score,
cohort, site, number of comorbidities, number of treat-
ment sessions, psychotropic medication status, primary
diagnosis, treatment type, age and sex; note: not all cov-
ariates were applicable for all samples). Principal com-
ponent analysis of the genetic data was performed and
twelve genomic principal components were associated
with the phenotype and included in the adult anxiety
sample analyses, three principal components in the adult
depression sample and one principal component in the
child sample to control for population stratiﬁcation.
Mixed linear model association (MLMA) analyses were
performed in each of the samples using GCTA MLMA-
LOCO88. A genetic relationship matrix (GRM) was
included to control for the random effects of genetic
similarity. Residualised therapy outcome was regressed on
the number of reference allele copies (0, 1 or 2), weighted
by the additive effect of the allele. Effect sizes and stan-
dard errors from the individual sample level analyses were
then combined in an inverse-variance weighted GWA
meta-analysis (GWAMA) in METAL89. The statistical
power of these analyses was estimated using the Genetic
Power Calculator90. The meta-analysis sample (n= 2724)
has 100% power to detect a variant explaining 2.4% of
variance, 80% power to detect variants explaining 1.5% of
the variance and 42% power to detect variants explaining
1% of the variance. To test for genetic heterogeneity
between the meta-analysis samples sign tests were per-
formed on the GWAS summary statistics. Pairs of sum-
mary statistics were examined using the SignTest package
(see Supplementary Materials for further details91).
Heritability of therapy outcome
Further analyses were performed to assess the com-
bined effects of genome-wide variants. The proportion of
variance in response accounted for by all assayed genetic
variants (h2SNP) was assessed with univariate genomic-
relationship-matrix restricted maximum likelihood
(GREML), performed in GCTA88. The GCTA-GREML
h2SNP estimates for treatment outcomes in the adult
anxiety, adult depression and child anxiety samples were
also combined in an inverse-variance weighted meta-
analysis92. Linkage disequilibrium score regression of the
GWAMA summary statistics was performed to provide a
second estimate93 (see Supplementary Materials). Our
sample of 2724 had 80 and 99% power to detect a SNP-
heritability of 33% and 50%, respectively94.
Polygenic scoring
Polygenic scoring was performed in PRSice v295. Poly-
genic scores were compiled in each of our cohorts after
clumping SNPs in linkage equilibrium (r2 < 0.25 per
250 kb window). Effect size estimates and P-values for
SNPs were drawn from GWAS summary statistics. For
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each GWAS phenotype, ﬁve polygenic scores were com-
puted, gradually incorporating more SNP effects, deter-
mined by the discovery phenotype GWAS P-value, using
thresholds of: p ≤ 0.01, p ≤ 0.05, p ≤ 0.1, p ≤ 0.5, p ≤ 1). An
individual's polygenic score is the sum of the GWAS effect
alleles that they carry in their genome, each weighted by
its effect size. Polygenic scores were standardised (mean
= 0, SD= 1) and regressed on residualised treatment
outcomes to test for an association. For each polygenic
score analysis 10,000 permutations were performed to
assess statistical signiﬁcance. As such, we tested for
associations between therapy outcomes and polygenic
scores for psychopathology (ADHD53, anxiety disorders11,
autism spectrum disorder54, MDD55 and schizophrenia56),
personality (neuroticism57, subjective well-being58 and
treatment-seeking behaviour59) and learning (educational
attainment60, intelligence61). An estimate of the statistical
power for each polygenic score analysis was computed
using AVENGEME96. We assumed that 95% of SNPs had
null effects and calculated power at ﬁve theoretical genetic
covariances (0.1, 0.2, 0.3, 0.4, 0.5). Power calculations
indicate that on average, polygenic score analyses have 80
to100% power to detect signiﬁcant associations, if the
discovery polygenic score trait has a genetic covariance
between 0.2 and 0.3 with the treatment outcome pheno-
type (see Supplementary Material). To test for genetic
heterogeneity between the meta-analysis samples we
performed a random effects meta-analysis of the poly-
genic scoring results, using the R package Metafor97.
Gene-wise and pathway association analysis
Gene-wise and pathway association analysis were per-
formed using MAGMA (for details see Supplementary
Materials).
Results
Clinical predictors of therapy outcome
An overview of the clinical and demographic char-
acteristics of each cohort are detailed in Table 1. The
effects of clinical covariates on symptom severity and
therapy outcomes were assessed in the adult anxiety
sample using a linear mixed model (Table 2). The effects
of clincal covariates have been reported previously for the
adult depression sample and the child anxiety sample, but
are also presented here for comparison. Analyses of the
adult anxiety sample indicate that, consistent with
broader therapy outcome literature, psychiatric comor-
bidity is associated with baseline severity (β= 0.14, SE=
0.03). Each additional comorbidity is equivalent to a 0.14
unit increase in baseline symptom severity. Of note,
compared with having a primary diagnosis of panic dis-
order, having panic disorder with agoraphobia is asso-
ciated with a 0.91 unit increase in baseline severity (β=
0.91, SE= 0.22).
Number of comorbidities and number of treatment
sessions have nominally signiﬁcant effects (P < 0.05) on
post-treatment scores (β= 0.09 and β=−0.02, respec-
tively). Here, higher comorbidity is associated with higher
symptom severity and attending more sessions is asso-
ciated with lower severity post-treatment. Higher baseline
severity is associated with a 0.39 unit increase in post-
therapy outcome.
Notably, the effects of clinical covariates were largely
consistent across the three meta-analysis samples. Num-
ber of comorbidities was associated with baseline severity
(β= 0.17, SE= 0.05) and post-treatment outcome (β=
0.22, SE= 0.06) in the adult depression cohort (Table 2).
Number of therapy sessions, concurrently taking psy-
chiatric medication and baseline symptom severity were
also associated with therapy outcomes at post-treatment
(β=−0.18, SE= 0.02; β= 0.2, SE= 0.08; β= 0.51, SE=
0.04, respectively). Number of comorbidities was asso-
ciated with higher baseline severity in the child anxiety
sample (β= 0.3, SE= 0.05). A primary diagnosis of social
anxiety (when compared with generalised anxiety) and
baseline severity were also associated with higher symp-
tom severity at post-treatment β= 1.34, SE= 0.18; β=
0.44, SE= 0.07, respectively—as reported in the original
paper35.
Table 1 Clinical and demographic characteristics of the
meta-analysis cohorts
Cohort: Adult
anxiety
Adult
depression
Child
anxiety
N: 972 832 920
Mean age (SD) 36.3 (11.0) 38.1 (11.8) 9.8 (2.2)
No. female (%) 644 (66.3) 558 (67.1) 516 (56.1)
Main diagnosis PD/AG MDD GAD
Frequency of main diagnosis (%) 409 (42.1) 832 (100) 339 (36.8)
Mean no. of comorbidities (SD) 0.9 (1.1) 0.3 (0.6) 0.6 (0.6)
No. taking psychotropic
medication (%)
199 (20.5) 291 (35.0) 140 (15.2)
Mean no. therapy sessions
completed (SD)
10.9 (6.0) 8.4 (2.0) 8.5 (0.5)
Mean standardised baseline
score (SD)
2.77 (1.0) 3.35 (1.0) 6.24 (1.0)
Mean standardised post-treatment
score (SD)**
1.31 (1.1) 1.99 (1.3) 2.98 (1.0)
PD/AG panic disorder with agoraphobia, MDD major depressive disorder, GAD
generalised anxiety disorder
*Cohorts: the adult anxiety cohort consists of 3 sub-cohorts (Bochum and
Braunschweig [3 sites], Karolinska PD iCBT [2 sites] and Panic-Net consortium
[2 sites]), the adult depression cohort is from the Karolinska, and the child
anxiety cohort consists of 11 sites
**Standard deviations differ from 1 at post treatment, because baseline SD was
used to standardise
Rayner et al. Translational Psychiatry           (2019) 9:150 Page 6 of 13
Association analyses
Phenotype and good quality genotype data were avail-
able for 972 individuals from the adult anxiety sample,
832 from the adult depression sample and 920 from the
child anxiety sample. After genotype quality control and
imputation there were a total of 4.71 million genetic
variants shared between the datasets that were included in
the analyses. We performed genome-wide mixed linear
model association analyses in each sample (MLMA-
LOCO, GCTA;88). No individual genetic variant was
associated with treatment outcomes in any of the indivi-
dual samples, after correction for multiple testing (P < 5 ×
10−8). However, several genetic loci surpassed a P-value
threshold suggestive of association (P < 10−5) and are
presented in the Supplementary Materials (S.Table 2–4; S.
Fig. 1–3).
Summary statistics from each sample analysis were then
meta-analysed in METAL89 (total n= 2724). No genetic
variant was associated with therapy outcome after cor-
rection for multiple testing. However, four independent
genetic loci on chromosomes 17, 3, 13 and 5 surpassed a P-
value threshold suggestive of association (P < 10−5; Fig. 1,
Table 3). Three out of the four genetic variants with P-
values <10−5 were not detected in any of the individual
sample analyses. Only one genetic variant (rs34724549,
chromosome 3) had a P-value <10−5 in both the full
meta-analysis and the adult anxiety sample. The
quantile–quantile plot of association P-values show no
departure from a chi-squared distribution expected under
the null hypothesis (Fig. 1; lambda= 0.98), which suggests
that there is unlikely to be underlying inﬂation of the
association statistics due to population stratiﬁcation.
To determine whether genetic effects were shared
between the cohorts, sign tests of the genetic variant
association effects were performed. Here, for each pair of
GWA summary statistics, we examined whether more
genetic variants were acting in the same direction than
one would expect by chance, using a binomial test (pre-
sented in the Supplementary Materials: S.Fig. 9 and S.
Table 9). However, these analyses, were underpowered to
provide strong evidence of shared genetic effects between
the meta-analysis samples, or the adult anxiety treatment
Table 2 Results of linear mixed model examining the effects of clinical covariates on standardised outcome measures in
the adult anxiety cohort (n= 972), in the adult depression cohort (n= 832) and in the child anxiety cohort (n= 920)
Adult anxiety Adult MDD Child anxiety
Baseline Post-treatment Baseline Post-treatment Baseline Post-treatment
Covariates β SE β SE β SE β SE β SE β SE
Age −0.01* 0 0 0 0.00 0.00 0.00 0.00 0.00 0.02 0.03 0.03
Male 0.08 0.07 0.09 0.07 0.04 0.07 −0.01 0.08 −0.04 0.06 −0.17 0.13
No. of comorbidities 0.14** 0.03 0.09* 0.03 0.17* 0.05 0.22** 0.06 0.30** 0.05 0.31* 0.11
No. of therapy sessions 0.02* 0.01 −0.02* 0.01 −0.03 0.01 −0.18** 0.02
Psychotropic medication 0.21* 0.09 0.03 0.09 −0.04 0.07 0.2* 0.08 0.12 0.10 0.35 0.20
Primary diagnosis: 1 v 2 0.91** 0.22 0.2 0.13 0.21* 0.09 0.33 0.19
Primary diagnosis: 1 v 3 0.99* 0.44 0.38 0.42 −0.04 0.08 1.34** 0.18
Primary diagnosis: 1 v 4 0.51 0.4 −0.39 0.38 0.07 0.11 0.55* 0.23
Primary diagnosis: 1 v 5 0.71* 0.24 −0.15 0.14 0.17 0.12 −0.42 0.26
Primary diagnosis: 1 v 6 −0.93 0.97 0.2 0.99
Primary diagnosis: 1 v 7 −0.02 0.61 0.39 0.58
Baseline score 0.39** 0.03 0.51** 0.04 0.44** 0.07
Adult anxiety cohort: Primary diagnoses ordered by frequency; 1= PD, panic disorder; 2= PD/AG, panic disorder with agoraphobia; 3= AG, agoraphobia; 4= SAD,
social anxiety disorder; 5= SP, speciﬁc phobia; 6= AD, alcohol dependence, 7= PTSD, post-traumatic stress disorder. Note: Fixed effects were calculated from linear
mixed models of outcomes and all available covariates modelled simultaneously. The random effects of cohort and site were included to account for the random
effects of primary outcome measure and between site effects; effects signiﬁcantly greater than 0 represent an association between the covariate and greater
symptom severity; Statistical signiﬁcance: *Nominal < 0.05, **Bonferonni p-value < 0.001
Adult MDD cohort: A linear model was used here, as this cohort did not vary by site (all participants recruited from the Internet Psychiatry Centre, Stockholm) or by
primary outcome measure (MADRS) or treatment type (100% iCBT) or primary diagnosis (100% MDD); Statistical signiﬁcance: *Nominal < 0.05, **Bonferonni p-value <
0.001
Child anxiety cohort: Primary diagnoses ordered by frequency; 1= GAD, generalised anxiety disorder; 2= SEP, separation anxiety disorder; 3= SAD, social anxiety
disorder; 4= SP, speciﬁc phobia; 5=OA, other anxiety disorder. Note: Fixed effects were calculated from linear mixed models of outcomes and all available covariates
modelled simultaneously. The random effects of cohort, site and treatment type were included to account for random effects between sites; effects signiﬁcantly
greater than 0 represent an association between the covariate and greater symptom severity ; Statistical signiﬁcance: *Nominal P-value < 0.05, **Bonferonni P-value
< 0.001
Rayner et al. Translational Psychiatry           (2019) 9:150 Page 7 of 13
cohorts. This is because GWA analyses were under-
powered to detect genetic effects in the ﬁrst place. As
such, there are only 33–43 independent genetic variants
associated at the highest level of signiﬁcance tested (P <
5 × 10−5). There is some indication of shared effects at
this P-value threshold between the child anxiety cohort
and each of the adult anxiety and MDD cohorts (65% and
60% consistency, respectively). However, this level of
sharing is not statistically signiﬁcant.
Heritability analysis
The proportion of variance in therapy outcomes
accounted for by all assayed SNPs was assessed using
GCTA-GREML88 in each cohort (see Supplementary
Materials, S.Table 5). The h2SNP estimates and standard
errors derived from each cohort were also combined in an
inverse-variance weighted meta-analysis92.The meta-
analysis estimate of SNP heritability was low and non-
signiﬁcant (h2SNP= 0.09, SE= 0.17).
Polygenic score analysis
We tested for associations between therapy outcomes
and polygenic scores across three domains: psycho-
pathology (ADHD53, anxiety disorders11, autism spectrum
disorder54, MDD55 and schizophrenia56), personality
(neuroticism57, subjective well-being58 and treatment-
seeking behaviour59) and learning (educational attain-
ment60, intelligence61) (Fig. 2; S.Tables 6–8). There were
Fig. 1 A Manhattan plot and a quantile–quantile plot of P-values from genetic associations with a CBT-outcome phenotype from the
genome-wide association meta-analysis of an adult anxiety sample (n= 972), an adult depression sample (n= 832), and a child anxiety
sample (n= 920; total n= 2724). Manhattan plot (left): The x-axis displays associated genetic variants, arranged by location on the chromosome.
The y-axis shows the strength of the association with the CBT-outcome phenotype. The red line represents the conventional threshold for genome-
wide signiﬁcance (P= 5 × 10−8) and the blue line represents a threshold suggestive of association (P= 10−5). QQ plot (right) of P-values expected
under the null chi-squared distribution (plotted on the x-axis) and P-values from the observed data (plotted on the y-axis) (Mean Chi2: 0.99; Lambda:
0.99; Lambda <1 implies no inﬂation)
Table 3 Independent genomic loci associated (P < 10−5) with therapy outcomes from the genome-wide association
meta-analysis of all cohorts (n= 2724)
BP SNP A1 A2 EAF (SE) β SE P Nearest genes (+/- 250kb)
CHR= 17 80965864 rs8068883 T C 0.32 (0.001) −0.16 0.03 1.70E-06 B3GNTL1, FLJ43681, METRNL, TBCD, ZNF750
CHR= 5 88929452 5:88929452_C_T T C 0.86 (0.01) −0.20 0.05 9.78E-06
CHR= 13 43631898 rs56686332 T C 0.08 (0.002) 0.25 0.06 5.44E-06 DNAJC15, ENOX1, EPSTI1, LINC00400
CHR= 3 118387584 rs34724549 A G 0.07 (0.007) 0.29 0.06 5.07E-06 IGSF11
Note: As no genetic variants were associated with outcome after correcting for multiple tests, those that were associated with p-values < 1 × 10−5 are presented here;
For regional plots for each of the loci please see supplemental material
CHR, chromosome; SNP, single nucleotide polymorphism; BP, base pair; A1, effect allele; A2, reference allele; EAF, effect allele frequency; β, effect size; SE, standard
error; P, P-value
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no associations between any of the polygenic scores tested
here and treatment outcomes in the adult anxiety sample.
However, the subjective well-being polygenic score was
nominally associated with therapy outcome in the child
sample (PT= 0.1, R2= 1.13%, β=−0.21, SE= 0.07,
P= 0.004), and the ASD polygenic score was nominally
associated with therapy outcome in the adult depression
sample (PT= 0.05, R2= 0.82%, β= 0.1, SE= 0.04, P= 0.02).
To both increase power to detect polygenic score
associations and to test for heterogeneity between the
cohorts, we performed random-effects model meta-
analyses of polygenic scoring summary statistics. We
found no associations between treatment outcomes and
polygenic scores from these meta-analyses. However,
there was some indication of heterogeneity. Eight out of
ten of the polygenic score analyses had signiﬁcant Q
statistics (P < 0.05; S.Table 6b). However, large conﬁdence
intervals around the I2 estimates indicate that overall,
analyses are underpowered to detect heterogeneity
between the three cohorts, without substantial bias. The
strongest evidence of heterogeneity comes from the meta-
analysis of the subjective well-being polygenic score
analyses (I2= 95%, 95% CI= 84%, 99.9%) and the MDD
polygenic score analyses (I2= 89%, 95% CI= 61.1%,
99.7%) (see Supplementary Material, S.Table 6b).
Gene-wise and pathways association analyses
No genes or pathways were associated with therapy
outcomes after corrections for multiple testing (gene-wise
Bonferroni P < 2.5 x 10−5; pathway Bonferroni P < 10−5).
The top genes (P < 10−4) and pathways (P < 10−3) are
detailed in the Supplementary Material (S.Tables 10–11).
Discussion
This study presents a new adult anxiety outcome sam-
ple with genetic data (n= 972) and the largest genome-
wide association meta-analyses of prognostic outcomes
following psychological therapy (n= 2,724).
First, we examined the effects of clinical covariates on
baseline symptom severity and prognostic outcome fol-
lowing CBT, using linear mixed models. As would be
expected, number of comorbidities was associated with
baseline severity in all three cohorts (adult anxiety: β=
0.14, SE= 0.03; adult depression: β= 0.17, SE= 0.05;
child anxiety: β= 0.3, SE= 0.05). The only consistent
predictor of poorer outcome was higher baseline severity
(adult anxiety: β= 0.39, SE= 0.03; adult depression: β=
0.51, SE= 0.04; child anxiety: β= 0.44, SE= 0.07). How-
ever, there was suggestive evidence of an association
between higher comorbidity and worse therapy outcomes
(adult anxiety: β= 0.09, SE= 0.03; adult depression: β=
0.22, SE= 0.06; child anxiety: β= 0.31, SE= 0.11). Better
adherence to treatment, indicated by number of treatment
sessions completed, was also associated with favourable
outcomes in the depression sample (β=−0.18, SE=
0.02), with weaker evidence of this relationship in the
adult anxiety sample (β=−0.02, SE= 0.01). These ana-
lyses suggest that, consistent with previous ﬁndings,
higher baseline symptom severity, higher comorbidity and
poor adherence to treatment are associated with poorer
therapy outcomes. Notably, a primary diagnosis of PD/AG
or SP was associated with more severe symptoms at
baseline (PD/AG β= 0.91, SE= 0.22; SP β= 0.71, SE=
0.24), but this did not impact symptoms post treatment.
This suggests that therapy outcome is independent of
primary diagnosis and that genomic studies of therapy
Fig. 2 Associations between polygenic scores (reﬂecting genetic propensity for psychopathology, personality, and learning) and therapy
outcomes. Beta coefﬁcients and 95% conﬁdence intervals (error bars) from univariable linear regressions examining the relationship between
treatment outcome and each polygenic score, in each of the meta-analysis cohorts, and subsequent meta-analysis; P-value thresholds selected in
these analyses are detailed in Supplementary Table 6; asterisk (*) indicates empirical p-value < 0.05, after 10,000 permutations
Rayner et al. Translational Psychiatry           (2019) 9:150 Page 9 of 13
outcome could combine treatment samples of adults with
varied primary diagnoses to increase power.
We performed genome-wide linear mixed model asso-
ciation analyses in three independent studies of prog-
nostic outcome following CBT, and then meta-analysed
the results (n= 2724). No genetic effects were detected in
these analyses. This result is consistent with the previous
genome-wide study of therapy outcomes in the child
sample40 and with other small GWAS of psychiatric
traits98. The meta-analysis sample (n= 2724) had 80%
power to detect variants explaining 1.5% of the variance
and 42% power to detect variants explaining 1% of the
variance. Therefore, it is not especially surprising that we
do not detect any variants at genome-wide signiﬁcance.
Typically, GWAS of psychological traits have required
tens of thousands of participants to detect SNPs at
genome-wide signiﬁcance43,99.
Our primary aim was to generate a cohort large enough
to examine the heritability of prognostic therapy out-
comes. However, the meta-analysis estimate of SNP her-
itability was low and non-signiﬁcant (h2SNP= 0.09, SE =
0.17). A sample size of 2724 has 80% and 99% power to
detect a SNP-heritability of 33% and 50%, respectively94.
To achieve 80% power to detect a heritability of 20%, a
sample of 4500 individuals will be required. A meta-
analysis of 2 799 individuals was sufﬁcient to detect a
signiﬁcant heritability estimate for therapy outcome to
antidepressant drugs (h2SNP= 0.42, SE = 0.18) and this
was the ﬁrst evidence of a genetic component for treat-
ments outcome of any kind44.
Genetic associations between therapy outcome and other
relevant phenotypes were investigated via polygenic score
analyses. There were no signiﬁcant associations in the adult
anxiety cohort. There were, however, nominal associations
between the Subjective Well-Being (SWB) polygenic score
and therapy outcomes in children, and also between the
Autism Spectrum Disorder (ASD) polygenic score and
treatment outcomes in the adult depression sample. In the
child sample, greater genetic propensity for SWB was
associated with lower symptoms at post-treatment (β=
−0.21, SE= 0.07, P= 0.004). In the adult depression
sample, increased genetic risk for ASD was nominally
associated with worse treatment outcomes (β= 0.1, SE=
0.04, P= 0.02). Here we reproduce the ﬁnding from the
original adult depression study47. It is worth noting, how-
ever, that for this current analysis, only two time-points
were used (pre-treatment and post-treatment) to compute
the therapy outcome phenotype, as these time-points were
consistent across our cohorts. The previous study47 mod-
elled 12 time-points, increasing sample size and power to
detect the effect (β= 0.09, P < 0.001).
Despite the availability of large GWAS samples, the
polygenic scores used here were largely insufﬁcient to
capture polygenic variation associated with therapy
outcome in the samples examined, after corrections for
multiple tests. This could indicate that power is atte-
nuated because of sample heterogeneity, or perhaps none
of the polygenic scores examined are close enough to our
treatment outcome phenotype. Power calculations indi-
cate that analyses were well powered to detect polygenic
associations if the genetic covariance between each of the
polygenic score traits and treatment outcomes in each
sample is more than 0.2. This suggests that the genetic
covariance between treatment outcome in these samples
and traits of interest is low.
There are additional factors that might explain the lack
of associations. Therapy outcome phenotypes were
adjusted for baseline severity, which might account for the
lack of association with the psychiatric disorder polygenic
scores. Such analyses explore whether genetic variants
associated with disorders predict therapy outcome above
and beyond initial disorder severity. However, the differ-
ential susceptibility hypothesis posits that genotypes
moderate the effects of both positive and negative envir-
onments100. As such, genotypes associated with onset of
depression following a stressful life event, would be
associated with favourable outcomes following psycholo-
gical therapy. However, we ﬁnd no evidence of such here.
Taken together, ﬁndings from SNP heritability and
polygenic score analyses suggest that there is likely to be
genetic heterogeneity between the samples examined here.
We tested for evidence of genetic heterogeneity using two
approaches. First performing sign tests for consistency of
the association statistics and also random-effects meta-
analyses of polygenic score statistics. However, these
analyses were underpowered. Therefore, we are unable to
make any strong conclusions as to whether substantial
heterogeneity exists, or whether disparate ﬁndings are
driven by noise, attributable to low sample size.
Therapygenetics studies will require much larger sam-
ples than presently available to detect genetic effects. This
study brings together clinical samples with sufﬁcient data
for genomic analysis. Such data are scarce, and the indi-
vidual cohorts studied are small for genetic analyses. Even
combined, they remain underpowered. Heterogeneity
between the samples and uncontrolled confounds com-
promise statistical power to detect genetic effects. How-
ever, there is a tradeoff between sample size and
heterogeneity, and we argue we are justiﬁed in that the
combined sample has considerably more power than any
of the individual samples alone. The aims of this study
were to build a cohort of sufﬁcient size to estimate the
SNP-heritability of psychological therapy outcomes. A
signiﬁcant estimate of heritability would allow for genetic
correlations with therapy outcomes to be examined. The
detection of signiﬁcant genetic correlations allows for the
joint analysis of traits, which can also boost statistical
power101,102. The strong genetic correlation between the
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anxiety disorders, depressive disorders and psychiatric
disorders in general suggests that meta-analyses of ther-
apy outcome could include treatment samples with vari-
able primary diagnoses to further increase power.
Combining clinical samples in meta-analyses has been a
successful approach towards understanding the genetic
architecture of psychiatric traits11,55,56. Larger meta-ana-
lyses, complemented by large, population-based initiatives,
which collect broad clinical, demographic, outcome and
genetic data, will be required to provide insights about the
genetic architecture underlying therapy outcome.
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